NPHC's burn rate is due to mostly R&D and with that they had to hire an additional 10 people, along with investor conferences, etc.
My point is that J&J probably does own their shelf space, but there is no way XCHO could afford that and this why we saw Cobroxin placed where it was on the shelves.
Market Data 
Markets 
AI
